Bayer HealthCare announced that the FDA has approved Finacea (azelaic acid) Foam, 15% for the topical treatment of the inflammatory...
For the relief of mild to moderate papular-pustular acne of the facial area. For the topical treatment of papulopustular rosacea.
Arcutis Biotherapeutics announced positive topline results from the ARRECTOR Pivotal Phase III trial evaluating roflumilast foam 0.3%, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents with scalp and body psoriasis.
Objective: We evaluated the efficacy of topical fixed-dose combination calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) on itch, itch-related sleep loss and HRQoL vs. foam vehicle.
Arcutis Biotherapeutics, Inc. announced new data from the STRATUM pivotal Phase III trial investigating roflumilast foam as a potential treatment for children ages 9 and above and adults with moderate to severe seborrheic dermatitis were presented orally at the Academy of Dermatology and Venereology (EADV) Congress.